Droxidopa
>98.0%
- Product Code: 74042
CAS:
23651-95-8
| Molecular Weight: | 213.19 g./mol | Molecular Formula: | C₉H₁₁NO₅ |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD00799030 | |
| Melting Point: | Boiling Point: | 549.8ºC | |
| Density: | 1.608g/cm3 | Storage Condition: | 2-8ºC |
Product Description:
Droxidopa is primarily used in the treatment of neurogenic orthostatic hypotension (NOH), a condition characterized by a significant drop in blood pressure upon standing, leading to dizziness, lightheadedness, and fainting. It works by being converted into norepinephrine in the body, which helps to constrict blood vessels and increase blood pressure, thereby alleviating symptoms associated with NOH. This makes it particularly beneficial for patients with conditions like Parkinson’s disease, multiple system atrophy, and pure autonomic failure, where NOH is a common complication. Additionally, droxidopa has been explored for its potential in improving mobility and reducing the risk of falls in elderly patients with NOH. Its ability to enhance norepinephrine levels also suggests possible applications in addressing fatigue and cognitive symptoms in certain neurological disorders, though these uses are still under investigation.
Product Specification:
| Test | Specification |
|---|---|
| APPEARANCE | White to Light yellow powder to crystal |
| PURITY | 97.5-100 |
| Infrared spectrum | Conforms to Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.050 | 10-20 days | $434.42 |
+
-
|
| 0.100 | 10-20 days | $779.13 |
+
-
|
Droxidopa
Droxidopa is primarily used in the treatment of neurogenic orthostatic hypotension (NOH), a condition characterized by a significant drop in blood pressure upon standing, leading to dizziness, lightheadedness, and fainting. It works by being converted into norepinephrine in the body, which helps to constrict blood vessels and increase blood pressure, thereby alleviating symptoms associated with NOH. This makes it particularly beneficial for patients with conditions like Parkinson’s disease, multiple system atrophy, and pure autonomic failure, where NOH is a common complication. Additionally, droxidopa has been explored for its potential in improving mobility and reducing the risk of falls in elderly patients with NOH. Its ability to enhance norepinephrine levels also suggests possible applications in addressing fatigue and cognitive symptoms in certain neurological disorders, though these uses are still under investigation.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :